VAP-1 Inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “VAP-1 Inhibitors- Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs based on VAP-1 Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
VAP-1 Inhibitors: Overview
Vascular adhesion protein-1 (VAP-1) is an ectoenzyme that oxidates primary amines in a reaction producing also hydrogen peroxide. VAP-1 on the blood vessel endothelium regulates leukocyte extravasation from the blood into tissues under physiological and pathological conditions. Inhibition of VAP-1, also known as AOC3 protein inhibitors by neutralizing antibodies and by several novel small-molecule enzyme inhibitors interferes with leukocyte trafficking and alleviates inflammation in many experimental models. Targeting of VAP-1 also shows beneficial effects in several other diseases, such as ischemia/reperfusion, fibrosis, and cancer. Moreover, soluble VAP-1 levels may serve as a new prognostic biomarker in selected diseases.
VAP-1 Inhibitors Emerging Drugs Chapters
This segment of the VAP-1 Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
VAP-1 Inhibitors Emerging Drugs
Further product details are provided in the report……..
VAP-1 Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different VAP-1 Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
VAP-1 Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses VAP-1 Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging VAP-1 Inhibitors drugs.
Report Highlights
DelveInsight’s, “VAP-1 Inhibitors- Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs based on VAP-1 Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
VAP-1 Inhibitors: Overview
Vascular adhesion protein-1 (VAP-1) is an ectoenzyme that oxidates primary amines in a reaction producing also hydrogen peroxide. VAP-1 on the blood vessel endothelium regulates leukocyte extravasation from the blood into tissues under physiological and pathological conditions. Inhibition of VAP-1, also known as AOC3 protein inhibitors by neutralizing antibodies and by several novel small-molecule enzyme inhibitors interferes with leukocyte trafficking and alleviates inflammation in many experimental models. Targeting of VAP-1 also shows beneficial effects in several other diseases, such as ischemia/reperfusion, fibrosis, and cancer. Moreover, soluble VAP-1 levels may serve as a new prognostic biomarker in selected diseases.
VAP-1 Inhibitors Emerging Drugs Chapters
This segment of the VAP-1 Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
VAP-1 Inhibitors Emerging Drugs
- TERN-201: Terns Pharmaceuticals
- PRX 167700: Proximagen
- TT-01025: TransThera Biosciences
Further product details are provided in the report……..
VAP-1 Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different VAP-1 Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in VAP-1 Inhibitors
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Gene therapies
- Small molecule
- Vaccines
- Polymers
- Peptides
- Monoclonal antibodies
- Product Type
VAP-1 Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses VAP-1 Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging VAP-1 Inhibitors drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence VAP-1 Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- In September 2020, Terns Pharmaceuticals announced that TERN-201, a semicarbazide-sensitive amine oxidase (SSAO) inhibitor, has been granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of non-alcoholic steatohepatitis (NASH).
- LG Chem reached an exclusive license agreement with TransThera Biosciences on August 2020 to research, develop, manufacture and commercialize TT-01025 in global region except Greater China and Japan.
- VAP-1 Inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
- What are the current treatment options available based on the VAP-1 Inhibitors?
- How many companies are developing therapies by working on VAP-1 Inhibitors?
- What are the principal therapies developed by these companies in the industry?
- How many therapies are developed by each company for VAP-1 Inhibitors to treat disease condition?
- How many emerging therapies are in early-stage, mid-stage, and late stage of development for VAP-1 Inhibitors?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other treatments?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the VAP-1 Inhibitors therapies?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies developed based on this mechanism of action?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for VAP-1 Inhibitors and their status?
- What are the results of the clinical studies and their safety and efficacy?
- What are the key designations that have been granted for the emerging therapies for VAP-1 Inhibitors?
- How many patents are granted and pending for the emerging therapies of VAP-1 Inhibitors?
- Terns Pharmaceuticals
- Proximagen
- TransThera Biosciences
- Pharmaxis
- Acorda Therapeutics
- R-Tech Ueno
- Pharmaxis
- TT-01025
- PRX 167700
- TERN-201
- Research programme: SSAO/VAP-1 protein inhibitors
- Research programme: VAP-1 SSAO enzyme inhibitors
- RTU 1096
- BI 1467335
Introduction
Executive Summary
VAP-1 Inhibitors: Overview
Structure
Mechanism of Action
Classification
Application
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
VAP-1 Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
VAP-1 Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
VAP-1 Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
PRX 167700: Proximagen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
TERN-201: Terns Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
TT-01025: TransThera Biosciences
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
VAP-1 Inhibitors Key Companies
VAP-1 Inhibitors Key Products
VAP-1 Inhibitors- Unmet Needs
VAP-1 Inhibitors- Market Drivers and Barriers
VAP-1 Inhibitors- Future Perspectives and Conclusion
VAP-1 Inhibitors Analyst Views
VAP-1 Inhibitors Key Companies
Appendix
Executive Summary
VAP-1 Inhibitors: Overview
Structure
Mechanism of Action
Classification
Application
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
VAP-1 Inhibitors – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
VAP-1 Inhibitors companies’ collaborations, Licensing, Acquisition -Deal Value Trends
VAP-1 Inhibitors Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Mid Stage Products (Phase II)
Comparative Analysis
PRX 167700: Proximagen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
TERN-201: Terns Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
TT-01025: TransThera Biosciences
Product Description
Research and Development
Product Development Activities
Inactive Products
Comparative Analysis
VAP-1 Inhibitors Key Companies
VAP-1 Inhibitors Key Products
VAP-1 Inhibitors- Unmet Needs
VAP-1 Inhibitors- Market Drivers and Barriers
VAP-1 Inhibitors- Future Perspectives and Conclusion
VAP-1 Inhibitors Analyst Views
VAP-1 Inhibitors Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for VAP-1 Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for VAP-1 Inhibitors
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for VAP-1 Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for VAP-1 Inhibitors
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
